ZOE STARCESKI: Open Payments
NPI 1982188033 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,702 in 81 payments from 11 companies in 2025. Trend: 2023 $2,099 · 2024 $2,392 · 2025 $1,702
Food & beverage: $1,702
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $934 |
| Axsome Therapeutics, Inc. | 13 | $361 |
| Vanda Pharmaceuticals Inc. | 3 | $88 |
| Alkermes, Inc. | 4 | $85 |
| Neurocrine BioSciences, Inc. | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: VRAYLAR, Auvelity, ARISTADA, INGREZZA, HETLIOZ, FANAPT, CAPLYTA, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
